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List of abbreviations: 1 
hs-cTn  =  high-sensitivity cardiac troponin 2 
AMI    =  acute myocardial infarction 3 
NSTEMI  = non-ST-segment elevation myocardial infarction 4 
ACS   = acute coronary syndrome 5 
VAS    = visual analogue scale 6 
ECG    =  electrocardiogram 7 
LoD    = limit of detection 8 
AUC    = area under the receiver-operating-characteristics curve 9 
NPV    = negative predictive value 10 
PPV    = positive predictive value 11 
CI    = confidence interval 12 
IQR    = interquartile range 13 
14 
3 
 
ABSTRACT  1 
Background: There is concern that high-sensitivity cardiac troponin (hs-cTn) may 2 
have low diagnostic accuracy in patients with low acute coronary syndrome (ACS)-3 
probability. 4 
Methods: We prospectively stratified patients presenting with acute chest discomfort 5 
to the emergency department (ED) into three groups according to their probability for 6 
ACS as assessed by the treating ED physician using a visual analogue scale (VAS): 7 
≤10%, 11-79%, ³80%, reviewing all information available at 90 minutes. hs-cTnT- 8 
and hs-cTnI-concentrations were determined in a blinded fashion. Two independent 9 
cardiologists adjudicated the final diagnosis.   10 
Results: Among 3828 patients eligible for analysis, 1189 patients had low (≤10%) 11 
probability for ACS. The incidence of non-ST-segment elevation myocardial infarction 12 
(NSTEMI) increased from 1.3% to 12.2% and 54.8% in patients with low, 13 
intermediate and high ACS-probability, respectively. The positive predictive value of 14 
hs-cTnT and hs-cTnI was low in patients with low ACS-probability and increased with 15 
the incidence of NSTEMI, while the diagnostic accuracy of hs-cTnT and hs-cTnI for 16 
NSTEMI as quantified by the area under the curve (AUC) were very high and 17 
comparable among all three strata (e.g. AUC hs-cTnI 0.96 (95%CI 0.94-0.97); 0.87 18 
(95%CI 0.85-0.89), and 0.89 (95%CI 0.87-0.92), respectively. Findings were 19 
validated using bootstrap analysis as an alternative methodology to define ACS-20 
probability. Similarly, higher hs-cTnT/I concentrations independently predicted all-21 
cause mortality within two years (e.g. hs-cTnT hazard ratio 1.39, 95%CI 1.27-1.52), 22 
irrespective of ACS-probability.  23 
Conclusions: Diagnostic and prognostic accuracy and utility of hs-cTnT and hs-cTnI 24 
remain high in patients with acute chest discomfort and low ACS-probability.  25 
26 
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Introduction 1 
Patients with symptoms suggestive of acute myocardial infarction (AMI) account for 2 
about 10% of all emergency department (ED) consultations (1). Rapid identification 3 
of AMI as a life-threatening disorder is important for the early initiation of appropriate, 4 
evidence-based therapy (2–4). Electrocardiography (ECG) and cardiac troponin 5 
(cTn) form the diagnostic cornerstones and complement clinical assessment (2–4). 6 
The introduction of sensitive and high-sensitivity cardiac troponin (hs-cTn) assays 7 
enabled precise measurement of cTn blood concentrations in the low-pathological 8 
and normal range (4), and more accurate diagnosis of non-ST-segment elevation 9 
myocardial infarction (NSTEMI) (5,6). 10 
Cardiomyocyte damage as quantified by hs-cTn blood concentrations is not 11 
unique to NSTEMI, but also associated with other cardiac disorders including heart 12 
failure, tachyarrhythmias, left ventricular hypertrophy, hypertensive crises, 13 
cardiomyopathies, valvular heart disease, myocarditis, and even stable coronary 14 
artery disease (1,2). Moreover, hs-cTn allowed the detection of cardiomyocyte 15 
damage as a probable consequence of severe primarily non-cardiac disease such as 16 
severe sepsis, septic shock, stroke, and pulmonary embolism (1,2). Concern of 17 
misinterpretation of these hs-cTn elevations as NSTEMI and patient harm associated 18 
with therapies for NSTEMI such as anticoagulation and coronary angiography 19 
applied in these non-AMI patients has led some authors to recommend withholding 20 
cTn testing in patients with low probability for acute coronary syndrome (ACS) (7,8). 21 
In contrast, practice guidelines highlight that NSTEMI frequently presents with 22 
atypical symptoms e.g. in women and elderly patients, and mandate high scrutiny for 23 
NSTEMI, which means ECG and cTn testing also in patients with atypical symptoms 24 
(2). These divergent recommendations highlight major gaps in knowledge and as a 25 
result uncertainty in clinical practice regarding cTn testing in patients with low 26 
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probability for ACS. 1 
Our aim was to address this inconsistency by directly comparing the 2 
diagnostic and prognostic accuracy of hs-cTnT and hs-cTnI among patients with low 3 
versus intermediate or high probability for ACS in patients presenting with any kind of 4 
acute chest discomfort to the ED. 5 
 6 
Materials and Methods 7 
The study design and population, as well as routine clinical assessment, adjudication 8 
of final diagnosis, and follow-up and clinical endpoints are described in the 9 
supplemental data. 10 
 11 
Quantification of ACS-probability  12 
ACS-probability was quantified using two complimentary methods. First, probability 13 
for ACS as the cause of the presenting symptom was quantified 90 minutes after 14 
presentation by the treating ED physician using a visual analogue scale (VAS, 15 
depicted in the supplemental data). At this time point, the ED physician had 16 
completed his/her clinical assessment including patient history, chest pain 17 
characteristics, detailed physical examination including vital signs and reviewed the 18 
ECG and the first local cTn measurement. We considered the levels of ≤10% as low, 19 
11-79% as intermediate and ³80% as high pre-test probability for ACS (9,10). 20 
Further details regarding the assessment of the ACS-probability of the ED-physician 21 
is given within the supplemental data. Second, to generate an alternative 22 
classification, we used bootstrap analysis to produce a predetermined prevalence 23 
different from the true prevalence of NSTEMI to simulate a low ACS-probability 24 
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setting. We 10’000 times randomly sampled 100 NSTEMI cases and 1900 non- 1 
NSTEMI cases to an incidence of NSTEMI of 2%.  2 
 3 
Measurements of hs-cTnT and hs-cTnI 4 
Blood samples for determination of hs-cTnT and hs-cTnI were collected at 5 
presentation and serially thereafter. After centrifugation, samples were frozen at -6 
80°C until assayed in a blinded fashion in a dedicated core laboratory. According to 7 
the manufacturer, the hs-cTnT assay (Roche Elecsys 2010, Roche Diagnostics, 8 
Rotkreuz, Switzerland) had a 99th percentile concentration of 14 ng/L with a 9 
corresponding co-efficient of variation (CV) of 10% at 13 ng/L (4). Limit of blank (LoB) 10 
and limit of detection (LoD) have been determined to be 3 ng/L and 5 ng/L. According 11 
to the manufacturer, the hs-cTnI assay (ARCHITECT STAT, Abbott Laboratories, IL) 12 
had a 99th percentile concentration of 26 ng/L with a corresponding co-efficient of 13 
variation (CV) of <5% and a limit of detection (LoD) of 2 ng/L (11–13). Further, two 14 
additional pre-commercial hs-cTnI assays and one s-cTnI assay were used. The 15 
detailed information from the manufacturer for these assays is given in the 16 
supplemental data.   17 
 18 
The European Society of Cardiology (ESC) hs-cTn 0/1h-algorithm 19 
The concept of the ESC 0/1h-algorithm is shown in Figure S2 and described in detail 20 
in the supplemental data.  21 
 22 
Statistical analysis 23 
Continuous variables are described as mean ± SD or median with interquartile range 24 
(IQR), categorical variables by numbers and percentages. Differences in baseline 25 
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characteristics between patients were assessed using the Mann-Whitney-U-test for 1 
continuous variables and the Pearson Chi-square test for categorical variables.  2 
Receiver-operating characteristics (ROC) curves were constructed to assess the 3 
sensitivity and specificity throughout the concentrations of hs-cTnT and hs-cTnI at 4 
presentation, at 1-h and 3-hour. Furthermore, ROC curves were constructed for early 5 
absolute changes of hs-cTnT and hs-cTnI within 1-hour, alone and in combination 6 
with hs-cTn concentrations at presentation. Logistic regression was used to combine 7 
hs-cTn concentrations at presentation with early changes in hs-cTn concentrations. 8 
Specificity, sensitivity, negative predictive value (NPV) and positive predictive value 9 
(PPV) for predefined cut-off-levels were calculated. We calculated the bootstrapped 10 
AUC and 95%-confidence intervals (CI) from the dataset simulating a low ACS-11 
probability defined as an NSTEMI incidence of 2%, calculated the AUC in each set 12 
and then calculated the mean AUC. Univariate and multivariate Cox regression 13 
analysis was used to calculate hazard ratios (HR) and 95%CI to reveal associations 14 
between hs-cTnT, hs-cTnI and long-term mortality of patients. We calculated the 15 
interaction p-value for the prognostic value of hs-cTn with levels of ACS-probability 16 
for all-cause mortality using a binary logistic regression model. Kaplan Meier analysis 17 
was performed using predefined cut-off-levels of hs-cTnT and hs-cTnI. All hypothesis 18 
testing was two-tailed and p-values <0.05 were considered statistically significant. 19 
Statistical analyses were performed using IBM SPSS Statistics for Windows, version 20 
22.0 (SPSS Inc, Chicago, IL) and the R statistical package (R Foundation for 21 
Statistical Computing, Vienna, Austria).   22 
 23 
Results 24 
 25 
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From April 2006 to August 2015, a total of 4323 patients were enrolled, of which 1 
3’828 patients were eligible for analysis (Figure S1). Baseline characteristics of the 2 
study population for the analyses of hs-cTnT are shown in Table 1 and for hs-cTnI in 3 
Table S1. Patients with low probability for ACS (VAS ≤10%) were significantly 4 
younger, less often had cardiovascular risk factors, established cardiovascular 5 
disease, and cardiovascular medication. Median time from chest pain onset to ED 6 
presentation was 5 hours (interquartile range 2 to 12 hours). 983 patients (25.7%) 7 
presented within two hours of chest pain onset to the ED.   8 
 9 
ACS-probability and incidence of NSTEMI 10 
Among 1189 patients who had low (≤10%) probability for ACS, NSTEMI was the 11 
adjudicated diagnosis in 15/1189 patients (1.3%). The incidence of NSTEMI in 12 
patients with intermediate (11-79%) and high (≥80%) probability for ACS was 12.2% 13 
(243/1986) and 54.8% (358/653), respectively. The prevalence of predefined 14 
alternative diagnoses including “unstable angina”, “cardiac symptoms of origin other 15 
than coronary artery disease” and “non-cardiac chest pain” are listed in Tables 2SA 16 
for the analyses of hs-cTnT and in Table 2SB for hs-cTnI.  17 
Concentrations of hs-cTnT and hs-cTnI at presentation and during serial 18 
sampling were significantly higher in patients with NSTEMI as compared to patients 19 
with other final diagnoses among all three ACS-probability strata (Table S3A and 20 
S3B).  The proportion of patients with elevated hs-cTnT and hs-cTnI concentrations 21 
obtained from the blinded study-specific samples taken at ED presentation across 22 
the different ACS-probabilities (low/intermediate/high) were 151 (13%), 629 (32%), 23 
and 463 (71%) patients with hs-cTnT ≥14 ng/l and 72 (7%), 292 (16%) and 336 24 
(55%) patients with hs-cTnI ≥26 ng/l. 25 
 26 
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Diagnostic accuracy of ACS-probability 1 
The diagnostic accuracy of the ACS-probability as quantified by the ED physician for 2 
an adjudicated diagnosis of ACS was 0.86 (95%CI 0.84-0.87). Diagnostic accuracy 3 
of hs-cTn for NSTEMI were very high and comparable among all three strata of ACS-4 
probability for hs-cTnT (low: AUC 0.94; 95%CI 0.87-1.00), intermediate: 0.89; 95%CI 5 
0.87-0.91, high: 0.90; 95%CI 0.87-0.92) and even higher in patients with low-ACS-6 
probability for hs-cTnI (AUC 0.96; 95%CI 0.94-0.97) as compared to patients with 7 
intermediate (AUC 0.87; 95%CI 0.85-0.89, p<0.01) and high ACS-probability (AUC 8 
0.89: 95%CI 0.87-0.92, p<0.01, Figure 1). These findings were consistent in all 9 
predefined subgroups (data not shown), for serial measurements of hs-cTnT and hs-10 
cTnI (Table S4), and for two additional pre-commercial hs-cTnI assays and one s-11 
cTnI assay (Table S5). 12 
The specificity for NSTEMI of the 99th-percentiles or 52ng/l as possible rule-in 13 
cut-off values for hs-cTnT and hs-cTnI was high. Increasing ACS-probability was 14 
associated with a decrease in specificity for both hs-cTnT and hs-cTnI (Table 2A-B). 15 
The PPV, which in contrast to specificity is depending on NSTEMI incidence, was low 16 
in patients with low ACS-probability and increased with increasing ACS-probability for 17 
both hs-cTnT and hs-cTnI. The distribution of final diagnoses in patients with hs-cTnT 18 
³14ng/L and patients with hs-cTnT ³52ng/L within each of the three ACS-probability 19 
strata is shown in Figure 2.  20 
Sensitivity and NPV were very high and comparable among all three strata 21 
using the LOD as a possible rule-out cut-off value for hs-cTnT and hs-cTnI. Using the 22 
99th percentiles recommended by the manufacturers, sensitivity and NPV were lower 23 
with hs-cTnI as compared to that obtained for hs-cTnT.  24 
 Additional samples after 1-hour of hs-cTnT were available in 3123/3828 25 
patients and of hs-cTnI in 2828/3548 patients. The diagnostic accuracy of absolute 26 
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hs-cTn changes for the diagnosis of NSTEMI in patients with low ACS-probability 1 
was very high after 1 hour for hs-cTnT (AUC, 0.91; 95%CI 0.79-1.00) and for hs-cTnI 2 
(AUC, 0.93; 95%CI 0.88-0.99) and was at least comparable to that in patients with 3 
intermediate or high likelihood of ACS (Table S4).  4 
 Combination of hs-cTn concentrations at presentation with early absolute 5 
changes was again very high in the low ACS-probability subgroup and comparable 6 
among all three strata: low ACS-probability hs-cTnT AUC 0.98 (95%CI 0.96-0.99), 7 
hs-cTnI AUC 0.94 (95%CI, 0.91-0.97); intermediate ACS-probability hs-cTnT AUC 8 
0.94; (95%CI 0.93-0.95), hs-cTnI AUC 0.91 (95%CI 0.89-0.93); high ACS-probability 9 
hs-cTnT AUC 0.93 (95%CI 0.90-0.96), hs-cTnI AUC 0.89 (95%CI 0.86-0.92). 10 
 In the bootstrap model with an NSTEMI incidence of 2%, diagnostic accuracy 11 
was very high for hs-cTnT (AUC, 0.93; 95%CI 0.89-0.96) and very high for hs-cTnI 12 
(AUC, 0.92; 95%CI 0.89-0.95). PPV was low and specificity high (Table S6). 13 
 The diagnostic performance of the ESC 0/1h-algorithm among the three 14 
different ACS-probability strata using hs-cTnT and hs-cTnI overall was very good 15 
(Figure 3, Table S7). Similar results were obtained when analyzing the subgroup of 16 
patients presenting very early (within 2h from chest pain onset, Table S8A-B). 17 
 18 
Outcome of patients according to likelihood level of ACS and cardiac troponin 19 
Patients with a low likelihood of ACS and a hs-cTnT level < 5 ng/L or a hs-cTnI <2 20 
ng/L (LOD) had an excellent prognosis with 0 deaths at 720 days. In patients with 21 
VAS ≤10% and hs-cTn above the 99th percentile (³14 ng/L respectively ³26 ng/L) 17 22 
deaths (11.3%) and correspondingly 9 deaths (12.5%) occurred at 720 days follow-23 
up. hs-cTnT was a strong predictor of death independent of age, gender and renal 24 
function (HR 1.39, 95%CI 1.27-1.52, p< 0.001). hs-cTnT was an even stronger 25 
predictor of all-cause mortality in patients with low ACS-probability (hazard ratio (HR) 26 
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2.16 (95%CI 1.51-3.09)) as compared to intermediate (HR 1.46 (95%CI 1.24-1.72)) 1 
and high ACS-probability (HR 1.30 (95%CI 1.12-1.50); interaction p-value <0.01). 2 
Similar findings were obtained for hs-cTnI (Figure 4).   3 
 4 
Discussion 5 
 6 
In this multicenter diagnostic study, we directly compared the diagnostic and 7 
prognostic accuracy of hs-cTnT and hs-cTnI among patients with low versus 8 
intermediate or high ACS-probability. We report seven major findings: First, in 9 
patients with low ACS-probability the prevalence of NSTEMI is low, resulting in a low 10 
PPV for hs-cTnT and hs-cTnI. Accordingly, the majority of patients with low ACS-11 
probability and elevated hs-cTnT/I blood concentrations will be found to have 12 
diagnoses other than NSTEMI. However, in patients with low ACS-probability, 13 
concentrations of hs-cTnT and hs-cTnI were significantly higher in patients with 14 
NSTEMI as compared to patients with other final diagnoses. The specificity of hs-15 
cTnT/I remained high at about 90% in patients with low ACS-probability when using 16 
the 99th percentiles and further increased when using higher cut-off values. Thus, the 17 
higher the hs-cTnT/I blood concentrations, the higher is the likelihood for NSTEMI 18 
also in patients with low ACS-probability. Second, with increasing ACS-probability 19 
NSTEMI prevalence and the PPV of hs-cTnT and hs-cTnI increased. In contrast, 20 
specificity for NSTEMI decreased with increasing ACS-probability. Third, sensitivity 21 
and NPV were very high and comparable among all three strata using the LOD as a 22 
possible rule-out cut-off value for hs-cTnT and hs-cTnI. Using the 99th percentiles 23 
currently recommended by the manufacturers (14ng/L for hs-cTnT and 26 ng/L for 24 
hs-cTnI), sensitivity and NPV were lower with hs-cTnI as compared to hs-cTnT. At 25 
first glance, this is surprising as both assays seem to have comparable diagnostic 26 
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accuracy for AMI (14), and hs-cTnI seems to have even higher analytical sensitivity 1 
as compared to hs-cTnT (11). The most likely explanation for this finding therefore is 2 
the biological non-equivalence of 26 ng/L for hs-cTnI versus 14ng/L for hs-cTnT as 3 
previously documented in two large studies (15,16). The biological equivalent hs-cTnI 4 
concentration corresponding to the 99th percentile for hs-cTnT was about half the 5 
approved 99th percentile for hs-cTnI in these studies (15,16). This major discrepancy 6 
in the currently recommended 99th-percentiles became also evident in this dataset: 7 
32.5% of patients had a hs-cTnT concentration ≥14 ng/L, whereas only 19.7% had a 8 
hs-cTnI concentration ≥26 ng/L. Thus, the 99th percentile variability between assays 9 
is substantial (17). To overcome the poor consistency in the composition of 10 
individuals enrolled for determining the 99th percentile, future studies comparing all 11 
contemporary sensitive and hs-assays within the same reference or disease 12 
population are warranted. Defining what constitutes the appropriate reference 13 
population is a topic of debate (18). Fourth, and perhaps of most importance, the 14 
diagnostic accuracy for hs-cTnT/I to diagnose NSTEMI in patients with acute chest 15 
discomfort and low ACS likelihood was very high (AUC 0.94 and 0.96) and 16 
comparable to that in patients with intermediate or high likelihood for ACS. Fifth, 17 
diagnostic accuracies for NSTEMI provided by early absolute changes of hs-cTn 18 
within 1-hour, alone or in combination with hs-cTn concentrations at presentation, 19 
provided very high and similar diagnostic accuracy in patients with low ACS-20 
probability as compared to the other strata. Sixth, the overall diagnostic performance 21 
of the ESC 0/1h-algorihm was very good among all ACS-probability strata, confirming 22 
the safety and efficacy of this approach also in patients with low ACS-probability. 23 
Seventh, hs-cTn was an independent predictor of all-cause mortality irrespective of 24 
the ACS-probability.  25 
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These findings corroborate and extend previous studies indicating the most 1 
appropriate clinical use of hs-cTnT and hs-cTn in patients with low ACS-2 
probability(3,5,6,14,19–25). In addition, these findings support the diagnostic use of 3 
hs-cTnT/I as a quantitative, and not as a dichotomous variable (“troponin-negative” 4 
and “troponin-positive”) (3,5,6,14,19–21). The proportion of patients who have 5 
NSTEMI rises with increasing blood concentrations of hs-cTn as well as with 6 
increasing absolute changes within serial measurements (6,14,16,19,21–23,26). 7 
Overall, the diagnostic performance of hs-cTnT and hs-cTnI in patients with low ACS-8 
probability supports current guideline recommendations that both the ECG and cTn 9 
must complement clinical assessment in all patients presenting with acute chest 10 
discomfort to the ED, also in patients with low ACS-probability.2,3  11 
To the best of our knowledge, this is the first prospective analysis explicitly 12 
assessing the role of hs-cTn-testing in patients with quantified low ACS-probability for 13 
ACS. Previous research focused predominantly on the evaluation of elevated cTn 14 
concentrations in unselected patients (22–25). In addition, these studies were either 15 
performed retrospectively (22,23,25) or in hospitalized patients only (24). In a 16 
retrospective analysis with 4’928 unselected patients that had cTnI testing as part of 17 
their ED-evaluation for various presenting symptoms and settings only 1.8% had a 18 
final diagnosis of Type I AMI (22). Similar to our findings Yiadom et al. (22) found that 19 
patients with high initial cTn concentrations had a much higher incidence of Type I 20 
NSTEMI and that sensitivity and specificity of s-cTn increased with serial testing. In 21 
contrast, a recent retrospective analysis (23) reported low specificity for hs-cTnT to 22 
diagnose NSTEMI when analyzing ED patients irrespective of symptoms and 23 
including patients with acute heart failure and patients with documented pulmonary 24 
embolism. 25 
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Many EDs use standard operating procedures (SOPs) for the initial 1 
assessments of patients presenting with common key symptoms such as acute chest 2 
discomfort, acute abdominal pain, or acute dyspnea. Our findings have major clinical 3 
implications since they clearly support the incorporation of hs-cTn testing, besides 4 
the immediate recording of an ECG, into the SOP for the assessment of patients 5 
presenting with acute chest discomfort to the ED. In contrast, cTn testing should not 6 
be part of the initial SOP with other presenting symptoms, but rather added once the 7 
evaluating physician suspects an AMI (27). It is very important to highlight, that our 8 
findings are specific for the ED-setting for patients presenting with any kind of chest 9 
discomfort, including “pressure”, “stinging”, “burning” or “pulling” and do not apply to 10 
patients in the ED without any chest discomfort, e.g. patients with a stroke (28,29). 11 
Further, our results do not apply to other settings, in which hs-cTn may be obtained, 12 
e.g. critical ill patients in the intensive care unit (30,31). 13 
The implementation of the kinetics of the marker could provide some 14 
reassurance regarding the widespread concern of too many false-positive results by 15 
ordering hs-cTn in patients with low likelihood of ACS. Serial measurements of hs-16 
cTnT-levels at 1-hour were available in 969/1189 patients with low ACS-probability. 17 
3.6% (35/969) patients showed a relevant rise of ³ 5 ng/L in 1-hour, identifying 10/13 18 
patients with the final diagnosis of an NSTEMI even though the ACS-probability for 19 
initially was considered to be ≤10%. Serial measurements of hs-cTn allow a better 20 
discrimination of ischemia-induced cardiac injury from cardiomyocyte damage by 21 
other cardiac disorders by a noninvasive, widely available test. Findings were 22 
confirmed by the ESC 0/1h-algorithm, which is based on the integrated use of hs-cTn 23 
concentrations at presentation and their absolute changes during serial sampling.  24 
Previous studies deriving and validating the ESC 0/1h-algorithm allowed as a 25 
variability for the 1-hour sample a period of +/-30 minutes. This rather liberal time 26 
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frame was intentionally chosen to reflect the challenge to adhere to a stricter 1 
phlebotomy collection timing in daily clinical practice. Accordingly, most institutions 2 
applying the ESC 0/1h-algorithm clinically should be able to do the 1h-sample in the 3 
same 30-90min time window as done in the initial studies (20,32–35).  4 
hs-cTn was an independent predictor of all-cause mortality across all ACS-5 
probability groups. This finding is in accordance to previous observations made in 6 
studies investigating the prognostic value of cTn in various other settings(36–38) and 7 
highlights that cardiomyocyte injury irrespective of its exact pathophysiological 8 
mechanism portend a worse prognosis (39). Therefore, beyond its diagnostic utility in 9 
the detection of NSTEMI, hs-cTn measurements provide a simple method to quantify 10 
the risk of death and thereby help in the delineation of a personalized management 11 
plan. 12 
Some limitations merit consideration when interpreting the findings of this study. 13 
First, in one of the two methods used to quantify ACS-probability, the treating 14 
physician was aware of the first clinical cTn measurement. While the ED physician 15 
was at all times blinded to the actual hs-cTnT and hs-cTnI concentrations used in this 16 
analysis, knowledge of the first clinical cTn concentrations likely introduced an 17 
unavoidable classification bias regarding the stratification of the likelihood levels for 18 
ACS. It is therefore very reassuring that our findings regarding diagnostic accuracy 19 
were confirmed using the alternative bootstrap simulation method. Furthermore, we 20 
assessed the AUC for serial measurements of both assays (hs-cTnT and hs-cTn), 21 
after 1 and 3 hours. The diagnostic accuracy of hs-cTn for patients with low likelihood 22 
of ACS increased for later sampling-points and was at least comparable to patients 23 
with intermediate or high likelihood of ACS. Second, this was a secondary analysis 24 
from a large ongoing multicenter study designed to improve the early diagnosis of 25 
AMI. As such, no specific power analysis was performed to justify the sample size for 26 
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this study. Third, even by experienced cardiologists applying current guideline 1 
recommendations (2,4,13,26), NSTEMI could not be reliably excluded in a small 2 
number of patients (2.5%, 108/4’232), although further clinical course did not reveal 3 
additional information indicating the diagnosis of AMI. Therefore, this subgroup had 4 
to be excluded from analysis. Fourth, we did not use sex-specific cut-off values in this 5 
analysis and thus cannot help broaden the scientific basis for the ongoing discussion 6 
regarding sex-specific cut-off values in the diagnosis of AMI (40). Fifth, we used the 7 
99th percentile as recommended by the manufacturers, calculated from two separate 8 
reference populations (hs-cTnT in 533 apparently healthy European subjects; hs-9 
cTnI in 449 apparently healthy US subjects) and not a 99th percentile derived from a 10 
similar single reference set (4,11,12). Sixth, we cannot generalize these findings to 11 
patients with terminal kidney failure requiring dialysis, since they were excluded from 12 
this study.  13 
 In conclusion, diagnostic and prognostic accuracy and utility of hs-cTnT/I 14 
remain very high in patients with acute chest discomfort and low ACS-probability for 15 
ACS when appropriately applied as a quantitative marker. The higher the hs-cTnT/I 16 
blood concentrations, the higher is the likelihood for NSTEMI also in patients with low 17 
ACS-probability. As the PPV remains low, the majority of patients with low ACS-18 
probability and elevated hs-cTnT/I blood concentrations will be found to have 19 
diagnoses other than NSTEMI. 20 
21 
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Tables  1 
Table 1 Baseline characteristics of the patients 
 
 VAS ≤ 10%  (n=1’189) 
VAS 11-79%  
(n=1’986) 
VAS ≥ 80 
 (n=653) p-Value* 
Age – y  52 [40, 64] 63 [51, 75] 70 [60, 79] <0.001 
Male gender – no. (%) 765 (64) 1324 (67) 494 (76) 0.006 
Early presenters (≤ 2 hours within 
chest pain onset) – no. (%) 
299 (25%) 541 (28%) 143 (22%) 0.021 
Time from chest pain onset to first 
study blood draw, hours 
5 (2, 14) 5 (2, 11) 5 (3, 12) 0.012 
Risk factors – no. (%)     
Hypertension 502 (42) 1‘318 (66) 529 (81) <0.001 
Hypercholesterolemia 370 (31) 1‘041 (52) 457 (70) <0.001 
Diabetes 135 (11) 354 (18) 167 (26) <0.001 
Current smoking 349 (29) 477 (24) 141 (22) <0.001 
History of smoking 383 (32) 739 (37) 288 (44) <0.001 
History – no. (%)     
Coronary artery disease 201 (17) 736 (37) 341 (52) <0.001 
Previous MI 147 (12) 512 (26) 242 (37) <0.001 
Previous revascularization 170 (14) 605 (31) 275 (42) <0.001 
Peripheral artery disease 31 (3) 114 (6) 67 (10) <0.001 
Previous stroke 49 (4) 111 (6) 47 (7) 0.022 
ECG findings – no. (%)     
Left bundle branch block 24 (2) 72 (4) 39 (6) 0.001 
ST-segment elevation 17 (1) 44 (2) 19 (3) 0.073 
ST-segment depression 38 (3) 136 (7) 138 (21) <0.001 
T-wave inversion 53 (4) 148 (7) 85 (13) <0.001 
No significant ECG 
abnormalities 
1057 (89) 1586 (80) 372 (57) <0.001 
Body mass index (kg/m2) 
Laboratory findings 
26 [23, 29] 27 [24, 30] 27 [24, 29] <0.001 
Creatinine clearance, 
mL/min/m2 
91 [78, 105] 83 [67, 99] 77 [61, 94] <0.001 
Chronic medication     
ASA 229 (19) 776 (39) 376 (58) <0.001 
Vitamin K antagonists 98 (8) 222 (11) 62 (10) 0.019 
B-blockers 248 (21) 773 (39) 296 (45) <0.001 
Statins 233 (20) 773 (39) 341 (52) <0.001 
ACEIs/ARBs 306 (26) 841 (42) 347 (53) <0.001 
26 
 
 1 
Numbers are presented as median [IQR] or numbers (%). VAS = visual analogue 2 
scale; ECG = electrocardiogram; BMI = body mass index; MI = myocardial infarction;  3 
hs-cTnT = high sensitive cardiac troponin T; ASA = Acetylsalicylic acid; ACE = 4 
angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker. 5 
*p-Value was calculated for differences in baseline characteristics between patients 6 
with VAS ≤ 10% and patients with VAS 11-79% and VAS ≥ 80 combined. 7 
Calcium antagonists 107 (9) 323 (16) 141 (22) <0.001 
Nitrates 51 (4) 217 (11) 139 (21) <0.001 
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Table 2A Diagnostic performance for NSTEMI of predefined cutoff-levels of hs-cTnT among all three strata  
   
Specificity,  
% (95%CI) 
PPV, 
% (95%CI) 
Sensitivity, 
% (95%CI) 
NPV, 
% (95%CI) 
Low likelihood hs-cTnT ≥ 5 ng/L 0.41 (0.38-0.44) 0.02 (0.01-0.03) 1.00 (0.70-1.00) 1.00 (0.99-1.00) 
VAS ≤ 10% hs-cTnT ≥ 14 ng/L 0.88 (0.86-0.90) 0.09 (0.05-0.15) 0.93 (0.68-1.00) 1.00 (0.99-1.00) 
  hs-cTnT ≥ 52 ng/L 0.99 (0.98-0.99) 0.26 (0.10-0.48) 0.40 (0.16-0.68) 0.99 (0.99-1.00) 
        
Intermediate likelihood hs-cTnT ≥ 5 ng/L 0.29 (0.27-0.31) 0.16 (0.14-0.18) 0.99 (0.97-1.00) 1.00 (0.99-1.00) 
VAS 11-79%  hs-cTnT ≥ 14 ng/L 0.76 (0.74-0.78) 0.33 (0.30-0.37) 0.86 (0.81-0.90) 0.98 (0.97-0.98) 
  hs-cTnT ≥ 52 ng/L 0.97 (0.96-0.98) 0.63 (0.55-0.71) 0.36 (0.30-0.43) 0.92 (0.90-0.93) 
        
High likelihood hs-cTnT ≥ 5 ng/L 0.14 (0.10-0.18) 0.58 (0.54-0.62) 1.00 (0.98-1.00) 0.98 (0.87-1.00) 
VAS ≥ 80 hs-cTnT ≥ 14 ng/L 0.58 (0.52-0.64) 0.73 (0.69-0.77) 0.95 (0.92-0.97) 0.90 (0.85-0.94) 
  hs-cTnT ≥ 52 ng/L 0.93 (0.89-0.95) 0.92 (0.87-0.95) 0.66 (0.61-0.71) 0.69 (0.64-0.74) 
Table 2B Diagnostic performance for NSTEMI of predefined cutoff-levels of hs-cTnI among all three strata 
   
Specificity, 
% (95%CI) 
PPV, 
% (95%CI) 
Sensitivity, 
% (95%CI) 
NPV, 
% (95%CI) 
Low likelihood hs-cTnI ≥ 2 ng/L 0.30 (0.27-0.32) 0.02 (0.01-0.03) 1.00 (0.68-1.00) 1.00 (0.98-1.00) 
VAS ≤ 10% hs-cTnI ≥ 26 ng/L 0.94 (0.93-0.96) 0.15 (0.08-0.26) 0.79 (0.49-0.95) 1.00 (0.99-1.00) 
  hs-cTnI ≥ 52 ng/L 0.96 (0.95-0.97) 0.10 (0.03-0.22) 0.36 (0.13-0.65) 0.99 (0.98-1.00) 
        
Intermediate likelihood hs-cTnI ≥ 2 ng/L 0.14 (0.13-0.16) 0.14 (0.12-0.16) 1.00 (0.98-1.00) 1.00 (0.98-1.00) 
VAS 11-79%  hs-cTnI ≥ 26 ng/L 0.90 (0.88-0.91) 0.44 (0.38-0.50) 0.56 (0.49-0.62) 0.94 (0.92-0.95) 
  hs-cTnI ≥ 52 ng/L 0.93 (0.92-0.95) 0.48 (0.41-0.55) 0.43 (0.36-0.49) 0.92 (0.91-0.93) 
        
High likelihood hs-cTnI ≥ 2 ng/L 0.06 (0.04-0.10) 0.57 (0.52-0.61) 1.00 (0.98-1.00) 1.00 (0.73-1.00) 
28 
 
VAS ≥ 80 hs-cTnI ≥ 26 ng/L 0.82 (0.77-0.86) 0.85 (0.81-0.89) 0.86 (0.82-0.89) 0.83 (0.78-0.87) 
  hs-cTnI ≥ 52 ng/L 0.87 (0.82-0.91) 0.88 (0.84-0.91) 0.78 (0.73-0.82) 0.76 (0.71-0.81) 
 
NSTEMI = non-ST-segment elevation myocardial infarction, PPV = positive predictive value, NPV = negative predictive value, VAS = 
visual analogue scale, hs-cTn = high sensitive Troponin.
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Figure Legends 
 
Figure 1: Receiver-operating characteristics (ROC) curves for high-sensitivity cardiac troponin (hs-cTn) T (left) and hs-cTnI 
(right) at presentation  
Receiver-operating characteristics (ROC) curves for the diagnostic performance of high-sensitivity cardiac troponin (hs-cTn) T (left) 
and hs-cTnI at presentation (right) to diagnose non-ST-segment elevation myocardial infarction (NSTEMI). Predefined cut-off levels 
are highlighted within the ROC Curves to demonstrate high specificity across different ACS-probability levels, for example, patients 
with hs-cTnT ³ 52 ng/L have a specificity ≈ 90% in all three ACS-probability levels.  
 
Figure 2: Pie charts for distribution of final diagnoses according acute coronary syndrome (ACS)-probability and elevated hs-
cTnT concentrations 
Distribution of final diagnoses in patients stratified according to acute coronary syndrome (ACS)-probability and high-sensitivity cardiac 
troponin T (hs-cTnT) levels. Shown for patients with hs-cTnT at presentation above the 99th percentile (³ 14 ng/L, top) and for patients 
with hs-cTnT above ³ 52 ng/L (bottom). CAD = coronary artery disease. 
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Figure 3: Diagnostic performance of the  European Society of Cardiology (ESC) hs-cTnT 0/1h-algorithm in patients with low, 
intermediate and high acute coronary syndrome (ACS)-probability 
Diagnostic performance of the European Society of Cardiology (ESC) hs-cTnT 0/1h-algorithm for triage towards rule-out, observe, and 
rule-in of non-ST-segment elevation myocardial infarction (NSTEMI) in patients stratified according to acute coronary syndrome 
(ACS)-probability into low, intermediate, and  high (*) if chest pain onset >3h; VAS = Visual analogue scale; NPV = Negative predictive 
value; PPV = Positive predictive value.  
 
Figure 4: Kaplan-Meier curves for the cumulative survival according to the ACS-probability group and displayed for different 
hs-cTnT (A) and hs-cTnI (B) levels 
Kaplan-Meier curves displaying survival during long-term follow-up (720 days) according to the ACS-probability group. On the top row 
(A) the green line displays high-sensitivity cardiac troponin (hs-cTnT) levels < 5 ng/L, the blue line hs-cTnT-levels ≥ 5 to < 14 ng/L and 
the red line hs-cTnT levels ≥ 14 ng/L. Hs-cTnI levels are displayed in a similar fashion in the bottom row (B). 
 
